Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF

Chaim O. Jacob, Luminita Pricop, Chaim Putterman, Michael N. Koss, Yi Liu, Maria Kollaros, Sarah A. Bixler, Christine M. Ambrose, Martin L. Scott, William Stohl

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Constitutive overexpression of B cell-activating factor belonging to the TNF family (BAFF) promotes development of systemic lupus erythematosus (SLE), and treatment of SLE mice with BAFF antagonists ameliorates disease. To determine whether SLE can develop de novo in BAFF-deficient hosts, BAFF-deficient New Zealand Mixed (NZM) 2328 (NZM.Baff-/-) mice were generated. In NZM.Baff-/- mice, spleen B cells (including CD5 + B1a and CD5- B1b B cells), germinal centers, Ig-secreting cells, and T cells were reduced in comparison to NZM.Baff -/- mice. Serum total Ig and autoantibody levels were reduced at 4-6 mo but approached wild-type levels with increasing age, indicating that autoreactive B cells can survive and secrete autoantibodies despite the complete absence of BAFF. At least some of these autoantibodies are nephrophilic in that glomerular deposition of total IgG and IgG1 (but not of IgG2a, IgG2b, or C3) was substantial in NZM.Baff-/- mice by 12-13 mo of age. Despite proliferative glomerulonephritis, highlighted by widespread glomerular hyaline thrombi, being common among NZM.Baff-/- mice by 6-7 mo of age, severe proteinuria and mortality were greatly attenuated. These results demonstrate that the lifelong absence of BAFF does not protect NZM 2328 mice from serological autoimmunity and renal pathology. Nevertheless, the character of the renal pathology is altered, and the mice are largely spared from clinically overt disease (severe proteinuria and premature death). These observations may have profound ramifications for the use of BAFF antagonists in human SLE and related diseases.

Original languageEnglish (US)
Pages (from-to)2671-2680
Number of pages10
JournalJournal of Immunology
Volume177
Issue number4
StatePublished - Aug 15 2006

Fingerprint

Autoimmunity
New Zealand
Pathology
Kidney
Systemic Lupus Erythematosus
Autoantibodies
B-Lymphocytes
Proteinuria
Immunoglobulin G
B-Cell Activating Factor
Premature Mortality
Hyalin
Germinal Center
Glomerulonephritis
Thrombosis
Spleen
T-Lymphocytes
Mortality
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. / Jacob, Chaim O.; Pricop, Luminita; Putterman, Chaim; Koss, Michael N.; Liu, Yi; Kollaros, Maria; Bixler, Sarah A.; Ambrose, Christine M.; Scott, Martin L.; Stohl, William.

In: Journal of Immunology, Vol. 177, No. 4, 15.08.2006, p. 2671-2680.

Research output: Contribution to journalArticle

Jacob, CO, Pricop, L, Putterman, C, Koss, MN, Liu, Y, Kollaros, M, Bixler, SA, Ambrose, CM, Scott, ML & Stohl, W 2006, 'Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF', Journal of Immunology, vol. 177, no. 4, pp. 2671-2680.
Jacob, Chaim O. ; Pricop, Luminita ; Putterman, Chaim ; Koss, Michael N. ; Liu, Yi ; Kollaros, Maria ; Bixler, Sarah A. ; Ambrose, Christine M. ; Scott, Martin L. ; Stohl, William. / Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. In: Journal of Immunology. 2006 ; Vol. 177, No. 4. pp. 2671-2680.
@article{47f4010e3eeb4106a24c41a4f68b7727,
title = "Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF",
abstract = "Constitutive overexpression of B cell-activating factor belonging to the TNF family (BAFF) promotes development of systemic lupus erythematosus (SLE), and treatment of SLE mice with BAFF antagonists ameliorates disease. To determine whether SLE can develop de novo in BAFF-deficient hosts, BAFF-deficient New Zealand Mixed (NZM) 2328 (NZM.Baff-/-) mice were generated. In NZM.Baff-/- mice, spleen B cells (including CD5 + B1a and CD5- B1b B cells), germinal centers, Ig-secreting cells, and T cells were reduced in comparison to NZM.Baff -/- mice. Serum total Ig and autoantibody levels were reduced at 4-6 mo but approached wild-type levels with increasing age, indicating that autoreactive B cells can survive and secrete autoantibodies despite the complete absence of BAFF. At least some of these autoantibodies are nephrophilic in that glomerular deposition of total IgG and IgG1 (but not of IgG2a, IgG2b, or C3) was substantial in NZM.Baff-/- mice by 12-13 mo of age. Despite proliferative glomerulonephritis, highlighted by widespread glomerular hyaline thrombi, being common among NZM.Baff-/- mice by 6-7 mo of age, severe proteinuria and mortality were greatly attenuated. These results demonstrate that the lifelong absence of BAFF does not protect NZM 2328 mice from serological autoimmunity and renal pathology. Nevertheless, the character of the renal pathology is altered, and the mice are largely spared from clinically overt disease (severe proteinuria and premature death). These observations may have profound ramifications for the use of BAFF antagonists in human SLE and related diseases.",
author = "Jacob, {Chaim O.} and Luminita Pricop and Chaim Putterman and Koss, {Michael N.} and Yi Liu and Maria Kollaros and Bixler, {Sarah A.} and Ambrose, {Christine M.} and Scott, {Martin L.} and William Stohl",
year = "2006",
month = "8",
day = "15",
language = "English (US)",
volume = "177",
pages = "2671--2680",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF

AU - Jacob, Chaim O.

AU - Pricop, Luminita

AU - Putterman, Chaim

AU - Koss, Michael N.

AU - Liu, Yi

AU - Kollaros, Maria

AU - Bixler, Sarah A.

AU - Ambrose, Christine M.

AU - Scott, Martin L.

AU - Stohl, William

PY - 2006/8/15

Y1 - 2006/8/15

N2 - Constitutive overexpression of B cell-activating factor belonging to the TNF family (BAFF) promotes development of systemic lupus erythematosus (SLE), and treatment of SLE mice with BAFF antagonists ameliorates disease. To determine whether SLE can develop de novo in BAFF-deficient hosts, BAFF-deficient New Zealand Mixed (NZM) 2328 (NZM.Baff-/-) mice were generated. In NZM.Baff-/- mice, spleen B cells (including CD5 + B1a and CD5- B1b B cells), germinal centers, Ig-secreting cells, and T cells were reduced in comparison to NZM.Baff -/- mice. Serum total Ig and autoantibody levels were reduced at 4-6 mo but approached wild-type levels with increasing age, indicating that autoreactive B cells can survive and secrete autoantibodies despite the complete absence of BAFF. At least some of these autoantibodies are nephrophilic in that glomerular deposition of total IgG and IgG1 (but not of IgG2a, IgG2b, or C3) was substantial in NZM.Baff-/- mice by 12-13 mo of age. Despite proliferative glomerulonephritis, highlighted by widespread glomerular hyaline thrombi, being common among NZM.Baff-/- mice by 6-7 mo of age, severe proteinuria and mortality were greatly attenuated. These results demonstrate that the lifelong absence of BAFF does not protect NZM 2328 mice from serological autoimmunity and renal pathology. Nevertheless, the character of the renal pathology is altered, and the mice are largely spared from clinically overt disease (severe proteinuria and premature death). These observations may have profound ramifications for the use of BAFF antagonists in human SLE and related diseases.

AB - Constitutive overexpression of B cell-activating factor belonging to the TNF family (BAFF) promotes development of systemic lupus erythematosus (SLE), and treatment of SLE mice with BAFF antagonists ameliorates disease. To determine whether SLE can develop de novo in BAFF-deficient hosts, BAFF-deficient New Zealand Mixed (NZM) 2328 (NZM.Baff-/-) mice were generated. In NZM.Baff-/- mice, spleen B cells (including CD5 + B1a and CD5- B1b B cells), germinal centers, Ig-secreting cells, and T cells were reduced in comparison to NZM.Baff -/- mice. Serum total Ig and autoantibody levels were reduced at 4-6 mo but approached wild-type levels with increasing age, indicating that autoreactive B cells can survive and secrete autoantibodies despite the complete absence of BAFF. At least some of these autoantibodies are nephrophilic in that glomerular deposition of total IgG and IgG1 (but not of IgG2a, IgG2b, or C3) was substantial in NZM.Baff-/- mice by 12-13 mo of age. Despite proliferative glomerulonephritis, highlighted by widespread glomerular hyaline thrombi, being common among NZM.Baff-/- mice by 6-7 mo of age, severe proteinuria and mortality were greatly attenuated. These results demonstrate that the lifelong absence of BAFF does not protect NZM 2328 mice from serological autoimmunity and renal pathology. Nevertheless, the character of the renal pathology is altered, and the mice are largely spared from clinically overt disease (severe proteinuria and premature death). These observations may have profound ramifications for the use of BAFF antagonists in human SLE and related diseases.

UR - http://www.scopus.com/inward/record.url?scp=33746890544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746890544&partnerID=8YFLogxK

M3 - Article

C2 - 16888029

AN - SCOPUS:33746890544

VL - 177

SP - 2671

EP - 2680

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -